Key result
Cardiovascular autonomic neuropathy is linked to ~2.4-fold higher risk of significant eGFR decline.
Why the study?
The study was conducted to investigate the association between cardiovascular autonomic neuropathy assessed by the coefficient of variation of the R-R interval and eGFR decline in patients with type 2 diabetes.
Does cardiovascular autonomic neuropathy predict the decline of eGFR in patients with type 2 diabetes?
Cohort (n=831)
No
Does cardiovascular autonomic neuropathy predict the decline of eGFR in patients with type 2 diabetes?
Assessing cardiovascular autonomic neuropathy via CVR-R identifies type 2 diabetes patients at higher risk of significant renal decline, specifically among those with macroproteinuria.
Answers are grounded in this paper and cite their sources.
CAN testing may flag macroproteinuric T2D patients for faster eGFR decline; leaves open whether screening improves renal outcomes.
AIMS/INTRODUCTION: To investigate the association between cardiovascular autonomic neuropathy (CAN) assessed by the coefficient of variation of the R-R interval and the reduction in the estimated glomerular filtration rate (eGFR) in patients with type 2 diabetes. MATERIALS AND METHODS: This retrospective observational cohort study enrolled type 2 diabetes patients who had their coefficient of variation of the R-R interval measured on an electrocardiogram from January 2005 to December 2018. CAN was defined using the reference coefficient of variation of the R-R interval value based on age and sex. The primary outcome was set as a 40% eGFR decline from baseline. Regression analyses using the Cox proportional hazards model were carried out to evaluate the association. RESULTS: Of the 831 patients, 118 (14.2%) were diagnosed with CAN. In the analysis of the primary outcome, the median follow-up period was 5.3 years, and 25 (21.2%) patients with CAN and 78 (10.9%) patients without CAN developed a 40% eGFR decline. In the univariate regression analysis, CAN was significantly associated with a 40% eGFR decline (hazard ratio 2.42, 95% confidence interval 1.54-3.80). In the multivariate analysis, CAN remained almost significant after adjusting for the prognostic risk factors for CAN and the decline in the renal function, and an interaction with proteinuria was found. In analyses for the interaction effect between CAN and proteinuria, the presence of CAN synergistically increased the risk of an eGFR decline in patients with macroproteinuria. CONCLUSIONS: CAN strongly increased the risk of a 40% eGFR decline from baseline, especially in type 2 diabetes patients with macroproteinuria.
No takes yet. Share an insight, caveat, or question.
Muramatsu et al. (2021) conducted a cohort in Type 2 diabetes (n=831). Cardiovascular autonomic neuropathy (CAN) vs. Absence of cardiovascular autonomic neuropathy was evaluated on First 40% eGFR decline from baseline (HR 2.42, 95% CI 1.54-3.80, p=0.0001). Cardiovascular autonomic neuropathy was significantly associated with a 40% eGFR decline (HR 2.42), synergistically increasing the risk of eGFR decline in patients with macroproteinuria.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: